Navigation Links
Advanced Life Sciences Announces Successful Thorough QT Study of Cethromycin
Date:2/19/2008

e passcode for the conference call is 82632306. Participants may pre-register for the call at https://www.theconferencingservice.com/prereg/key.process?key=RGRXWMYHV

A telephone replay of the call will also be available for 48 hours. Callers may access the telephone replay by dialing (domestic) 888-286-8010 or 617-801-6888 (international), passcode 10008184.

About Community Acquired Pneumonia (CAP)

CAP is the sixth most common cause of death in the United States. CAP and other respiratory tract infections are caused by pathogens such as Streptococcus pneumoniae and Haemophilus influenzae. Approximately 5.6 million cases of CAP are diagnosed each year in the United States with 10 million physician visits, resulting in an estimated total annual expenditure of $2 billion dollars for prescribed antibiotics to treat CAP. CAP is potentially fatal if not treated properly, and the bacteria that cause CAP are developing resistance to current standard of care treatments.

Macrolides and penicillins are currently the first-line treatments for respiratory tract infections such as CAP. As macrolide and penicillin resistance grows and has the potential to cause more clinical failures, there is a need for new antibiotics with unique mechanisms of action that can overcome this emerging resistance.

About Cethromycin

Cethromycin has shown higher in vitro potency and a broader range of activity than macrolides against Gram-positive bacteria associated with respiratory tract infections. In in vitro tests, cethromycin appears to be effective against penicillin- and macrolide-resistant bacteria. Cethromycin has a mechanism of action that may slow the onset of future bacterial resistance.

In addition to its utility in CAP, cethromycin is also being investigated for the prophylactic treatment of inhalation anthrax post-exposure. The FDA has des
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
4. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
5. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
6. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
7. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
11. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... months endedChange %  30 September 201430 September 2013Turnover 546,011 , ... , 384,242 , 339,113 , 13.3 ... , 49.5 Medical Insurance Administration Service Income , ... Devices and Accessories Sales , 94,580 , 142,683 ... 2,917 , 9,219 , (68.4) Impairment Loss on ...
(Date:11/26/2014)... Nov. 26, 2014   Royal Philips ... announced expanded availability of its portfolio of ... wDR, MobileDiagnost Opta[i] , ProGrade and PrimaryDiagnost[ii]. With ... available in the U.S., and availability of all ... offers Philips, customers innovative solutions designed to meet ...
(Date:11/26/2014)... , Nov. 26, 2014 Lexicon Pharmaceuticals, ... the completion of previously announced concurrent financing transactions ... fees and estimated offering expenses, Lexicon anticipates net ...  The transactions consisted of: , a ... pursuant to a registration statement that has been ...
Breaking Medicine Technology:Golden Meditech Announces 2014 / 2015 Interim Results 2Golden Meditech Announces 2014 / 2015 Interim Results 3Golden Meditech Announces 2014 / 2015 Interim Results 4Golden Meditech Announces 2014 / 2015 Interim Results 5Golden Meditech Announces 2014 / 2015 Interim Results 6Golden Meditech Announces 2014 / 2015 Interim Results 7Golden Meditech Announces 2014 / 2015 Interim Results 8Philips expands global reach of diagnostic X-Ray solutions 2Philips expands global reach of diagnostic X-Ray solutions 3Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3
... at High,Risk , ,WASHINGTON, March 9, 2007 ... history of end-stage renal disease (ESRD), and,these individuals appear ... reports a study in the April Journal of,the American ... disease is more frequent in,African-Americans, who are also at ...
... Pharmaceuticals,Inc. (OTCBB:CGXP), a biopharmaceutical company focused on,infectious ... catheter,treated with a Ceragenin compound demonstrated virtually ... In the study, polyurethane catheters treated with ... along with an,untreated catheter. At day 21, ...
Cached Medicine Technology:Nearly 1 in 10 Americans Has A Relative With Kidney Failure 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 2Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm,Formation in 21 Day Study 3
(Date:11/28/2014)... The Alternative Health Therapies ... five years. The industry has been buoyed by ... either alternative to conventional Western medicine or complementary ... David Whytcross, “industry revenue has been further boosted ... insurance membership.” Meanwhile, improving economic conditions following the ...
(Date:11/28/2014)... 27, 2014 (HealthDay News) -- Planning on seconds at ... heartburn -- clinically known as gastroesophageal reflux disease (GERD) -- ... Jordan Josephson, an ear, nose and throat specialist at Lenox ... to help manage GERD on Thanksgiving: Pace ... least two small meals throughout the day. It,s also a ...
(Date:11/28/2014)... November 28, 2014 An inventor and dental ... on a patient’s filling and it was almost impossible to ... curing light," she said. , The patent-pending Access Light allows ... access to areas of the mouth, as well as avoids ... and safety. Easy to use and clean, it also helps ...
(Date:11/28/2014)... November 28, 2014 A newly released ... an overview of the influenza virus that will soon be ... , The article begins with a brief explanation of ... symptoms. It reminds families that children under the age of ... from chronic diseases, such as heart and lung diseases, asthma, ...
(Date:11/28/2014)... November 28, 2014 "Most of my life, ... to use crutches," said an inventor from Findlay, Ohio. "I ... way to support my foot, which inspired me to invent ... offer a convenient way to support an injured foot. The ... It eliminates the need for crutches. The design redistributes weight ...
Breaking Medicine News(10 mins):Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Alternative Health Therapies in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:Don't Let Chronic Heartburn Spoil Your Thanksgiving Feast 2Health News:How Flu Vaccines Can Impact Families Is Discussed in New Article from Community Health Center of Snohomish County 2
... gastrointestinal bleeding accounts for approximately 20% of emergency ... has been used as a first-line treatment option ... be used as a safe diagnostic and treatment ... refractory to endoscopic treatment. The incidence of rebleeding ...
... , , , VIENNA, ... Industries Ltd. (Nasdaq: TEVA ), today announced results ... corticosteroids (ICSs) in a "real-life" asthmatic population. The study ... to effectively treat both large and small airway inflammation, to ...
... , WASHINGTON, Sept. 16 Antidepressant drug ... year, has been known to cause birth defects, but the ... a Philadelphia court has heard. , , ... the drug and urged scientists to conceal Paxil,s risks. The ...
... , , BRAINTREE, Mass. and ... HAE ) announced today that it has signed a ... a cooperative of community blood centers. The contract provides ... of innovative blood management software products, including Prelude and Interlude, ...
... finds supervised exercise has better results , WEDNESDAY, Sept. ... shockwave treatment for relieving chronic shoulder pain, according to ... to treat shoulder pain, even though a number of ... Norwegian researchers studied 104 men and women, aged 18 ...
... , , WASHINGTON, Sept. ... Orthotic and Prosthetic Association today announced that Senators Tom Harkin ... Miller, and Lincoln Diaz-Balart are recipients of their joint organizations, ... view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/aopa/40117/ ...
Cached Medicine News:Health News:Study Demonstrates That QVAR(R) is More Cost-Effective Than Other Inhaled Corticosteroid (ICS) Asthma Therapy Options 2Health News:Study Demonstrates That QVAR(R) is More Cost-Effective Than Other Inhaled Corticosteroid (ICS) Asthma Therapy Options 3Health News:Study Demonstrates That QVAR(R) is More Cost-Effective Than Other Inhaled Corticosteroid (ICS) Asthma Therapy Options 4Health News:Glaxo Official Memo Urged Scientists to Withhold Information About Paxil's Risks, Trial Hears; Pharmaceutical Industry Today Offers Complete News Coverage 2Health News:Haemonetics Signs Comprehensive Agreement with Blood Centers of America 2Health News:Shockwave Treatment May Not Be Best for Shoulder Pain 2Health News:Video: Members of Congress Receive Legislative Awards From National Amputee Organizations 2Health News:Video: Members of Congress Receive Legislative Awards From National Amputee Organizations 3
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... German Craftsmanship have produced ... in the world. Ocutek ... to you! Only holders ... certificate, which requires and ...
... Ophthalmics offers the most comprehensive family ... Instruments for Cataract incision, Glaucoma filtration, ... coagulation is achieved with minimal tissue ... Straight eraser styles are available in ...
Medicine Products: